Immunic Inc (IMUX)

$0.66 +0.01 (0.93%)
Market Cap 75.18M
Revenue (ttm) 0.00
Net Income (ttm) -100.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 938,800
Avg Vol 1,461,816
Day's Range N/A - N/A
Shares Out 120.29M
Stochastic %K 54%
Beta 1.54
Analysts Strong Sell
Price Target $5.53

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology
Sector: Healthcare
Phone: 332 255 9818
Website: imux.com
Address:
1200 Avenue of the Americas, Suite 200, New York, United States
BoomJBoomJ
BoomJBoomJ Feb. 3 at 9:04 PM
$IMUX Reevaluated my investment today, still very bullish and confident that they will either get the funding through an offering or a partnership to finish phase 3. The data from phase 2 for PPMS is too good, Ocrevus is the only FDA approved drug to treat PPMS and vido calcium beat Ocrevus in regard to reducing 24 week confirmed disability progression (30-33% vs Ocrevus 25%)with a much safer profile. And with neuroprotective effects seen from phase 2 (which is very important for PPMS) I just can’t see why BP’s would not be lining up at the door to partner or acquire Immunic. If phase 3 confirms results from phase 2 or even shows a slight decrease in efficacy (common outcome) then I can’t figure out a reason why the FDA would not approve. What am I missing?
2 · Reply
TREBLALBERT
TREBLALBERT Feb. 2 at 8:36 PM
$IMUX there is an ATM in progress IMO
3 · Reply
Cattitude
Cattitude Feb. 2 at 7:23 PM
$IMUX biogen target perhaps? 🤔
1 · Reply
TREBLALBERT
TREBLALBERT Feb. 2 at 5:58 PM
$IMUX We need a close above 0.65 and then we can think about 0.7 Come on, come on, let's go.
1 · Reply
Om05
Om05 Feb. 2 at 5:48 PM
$IMUX Sleepy Dr.witt 😴😴
0 · Reply
Mattjen
Mattjen Feb. 2 at 4:04 PM
$IMUX February looks pivotal. Cash pressure forces action, yet there’s no RS or panic dilution behavior. New 13G just dropped: 6.85% institutional ownership (8.2M shares). That’s not dumb money. Rising volume + calm management = positioning ahead of a partnership, not distress. Smart money doesn’t wait for press releases
0 · Reply
Mattjen
Mattjen Feb. 2 at 4:00 PM
$IMUX haha... keep calling me a clown... I love it
1 · Reply
Tradergrows
Tradergrows Feb. 2 at 3:58 PM
$IMUX
0 · Reply
Mattjen
Mattjen Jan. 31 at 8:18 PM
$IMUX listen to the broke bears saying IMUX is dead, or trust the Janus Henderson Group. Don't listen to the broke people on this board. Follow the smart money. Don't time the market..... time in the market will always win.
0 · Reply
Om05
Om05 Jan. 31 at 4:02 AM
$IMUX Dr.Witt is sleeping .😴
0 · Reply
Latest News on IMUX
Immunic Highlights 2025 Accomplishments and Upcoming Milestones

Jan 7, 2026, 6:30 AM EST - 27 days ago

Immunic Highlights 2025 Accomplishments and Upcoming Milestones

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Nov 26, 2025, 6:30 AM EST - 2 months ago

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 6:30 AM EST - 2 months ago

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Immunic to Participate in Industry and Investor Conferences in November

Oct 29, 2025, 6:30 AM EDT - 3 months ago

Immunic to Participate in Industry and Investor Conferences in November

Immunic to Participate in Scientific and Investor Conferences in October

Oct 1, 2025, 6:30 AM EDT - 4 months ago

Immunic to Participate in Scientific and Investor Conferences in October

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Sep 25, 2025, 6:30 AM EDT - 4 months ago

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Sep 9, 2025, 6:30 AM EDT - 5 months ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Immunic to Participate in Investor and Scientific Conferences in September

Sep 4, 2025, 6:30 AM EDT - 5 months ago

Immunic to Participate in Investor and Scientific Conferences in September

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 6:30 AM EDT - 6 months ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 24, 2025, 6:30 AM EDT - 8 months ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Jun 9, 2025, 5:51 PM EDT - 8 months ago

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 5, 2025, 6:30 AM EDT - 8 months ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 3, 2025, 4:01 PM EDT - 8 months ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Jun 2, 2025, 6:30 AM EDT - 8 months ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 29, 2025, 7:05 AM EDT - 8 months ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

Immunic, Inc. Announces Proposed Public Offering

May 28, 2025, 4:02 PM EDT - 8 months ago

Immunic, Inc. Announces Proposed Public Offering

Immunic to Participate in Scientific and Industry Conferences in May

May 2, 2025, 6:30 AM EDT - 9 months ago

Immunic to Participate in Scientific and Industry Conferences in May

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 30, 2025, 7:30 AM EDT - 9 months ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Apr 28, 2025, 2:09 AM EDT - 10 months ago

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 10, 2025, 1:00 PM EDT - 10 months ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 10 months ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Apr 1, 2025, 6:30 AM EDT - 11 months ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Immunic to Participate in Scientific and Investor Conferences in March

Mar 3, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Scientific and Investor Conferences in March

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 26, 2025, 6:30 AM EST - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 20, 2025, 7:30 AM EST - 1 year ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Immunic to Participate in Investor and Scientific Conferences in February

Feb 4, 2025, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in February

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Jan 7, 2025, 6:30 AM EST - 1 year ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Immunic, Inc. to Participate in Investor Conference in December

Nov 26, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Participate in Investor Conference in December

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 13, 2024, 6:30 AM EST - 1 year ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 8:37 AM EST - 1 year ago

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Oct 22, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Sep 4, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 6:55 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Immunic Appoints Jason Tardio as Chief Operating Officer and President

Jul 9, 2024, 6:30 AM EDT - 1 year ago

Immunic Appoints Jason Tardio as Chief Operating Officer and President

Immunic to Participate in Industry and Scientific Conferences in June

May 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry and Scientific Conferences in June

Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript

May 8, 2024, 2:20 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

Immunic to Participate in Investor and Scientific Conferences in May

May 6, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in May

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

May 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Apr 30, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Mar 20, 2024, 6:30 AM EDT - 2 years ago

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

BoomJBoomJ
BoomJBoomJ Feb. 3 at 9:04 PM
$IMUX Reevaluated my investment today, still very bullish and confident that they will either get the funding through an offering or a partnership to finish phase 3. The data from phase 2 for PPMS is too good, Ocrevus is the only FDA approved drug to treat PPMS and vido calcium beat Ocrevus in regard to reducing 24 week confirmed disability progression (30-33% vs Ocrevus 25%)with a much safer profile. And with neuroprotective effects seen from phase 2 (which is very important for PPMS) I just can’t see why BP’s would not be lining up at the door to partner or acquire Immunic. If phase 3 confirms results from phase 2 or even shows a slight decrease in efficacy (common outcome) then I can’t figure out a reason why the FDA would not approve. What am I missing?
2 · Reply
TREBLALBERT
TREBLALBERT Feb. 2 at 8:36 PM
$IMUX there is an ATM in progress IMO
3 · Reply
Cattitude
Cattitude Feb. 2 at 7:23 PM
$IMUX biogen target perhaps? 🤔
1 · Reply
TREBLALBERT
TREBLALBERT Feb. 2 at 5:58 PM
$IMUX We need a close above 0.65 and then we can think about 0.7 Come on, come on, let's go.
1 · Reply
Om05
Om05 Feb. 2 at 5:48 PM
$IMUX Sleepy Dr.witt 😴😴
0 · Reply
Mattjen
Mattjen Feb. 2 at 4:04 PM
$IMUX February looks pivotal. Cash pressure forces action, yet there’s no RS or panic dilution behavior. New 13G just dropped: 6.85% institutional ownership (8.2M shares). That’s not dumb money. Rising volume + calm management = positioning ahead of a partnership, not distress. Smart money doesn’t wait for press releases
0 · Reply
Mattjen
Mattjen Feb. 2 at 4:00 PM
$IMUX haha... keep calling me a clown... I love it
1 · Reply
Tradergrows
Tradergrows Feb. 2 at 3:58 PM
$IMUX
0 · Reply
Mattjen
Mattjen Jan. 31 at 8:18 PM
$IMUX listen to the broke bears saying IMUX is dead, or trust the Janus Henderson Group. Don't listen to the broke people on this board. Follow the smart money. Don't time the market..... time in the market will always win.
0 · Reply
Om05
Om05 Jan. 31 at 4:02 AM
$IMUX Dr.Witt is sleeping .😴
0 · Reply
Tradergrows
Tradergrows Jan. 31 at 2:12 AM
$IMUX I hope we get some good news next week.🤞It’s about time for an update, lots of earnings reports coming soon. Maybe the silence is so great because there’s a big deal coming. Maybe Vittardio is a genius. Maybe…
0 · Reply
coujatrader
coujatrader Jan. 31 at 12:33 AM
$IMUX average down and down and down by more and more and more to go up. Isn’t that how it’s supposed to work
0 · Reply
Jw242
Jw242 Jan. 30 at 5:03 PM
$IMUX been trying to keep quiet but begging for a pump before the offering.
1 · Reply
Mattjen
Mattjen Jan. 30 at 3:01 PM
$IMUX when you know, you know
0 · Reply
Mattjen
Mattjen Jan. 30 at 2:59 PM
$IMUX https://www.cnbc.com/2026/01/29/roche-sanofi-earnings-pharma-drug-pipeline-obesity.html
1 · Reply
Mattjen
Mattjen Jan. 29 at 2:57 PM
$IMUX https://www.google.com/search?q=warren+buffet+buy+when+others+fear&oq=warren+buffet+buy+when+others+fear&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIICAEQABgWGB4yCAgCEAAYFhgeMggIAxAAGBYYHjIICAQQABgWGB4yCAgFEAAYFhgeMg0IBhAAGIYDGIAEGIoFMg0IBxAAGIYDGIAEGIoFMgcICBAAGO8FMgcICRAAGO8FMgoIChAAGIAEGKIEMgcICxAhGI8CMgcIDBAhGI8C0gEJMTE3NjlqMGo3qAIQsAIB8QWxig8ygeeN1w&client=ms-android-att-us-rvc3&sourceid=chrome-mobile&ie=UTF-8#fpstate=ive&vld=cid:e6979aea,vid:PwlRov5t0Zk,st:0
0 · Reply
Mattjen
Mattjen Jan. 29 at 2:55 PM
$IMUX “Be fearful when others are greedy and greedy when others are fearful.” - Warren Buffet
0 · Reply
Mattjen
Mattjen Jan. 29 at 2:52 PM
$IMUX
0 · Reply
Mattjen
Mattjen Jan. 29 at 2:51 PM
$IMUX don't let the bears pull you down. Remove emotions and buy the dip.
0 · Reply
AitorMenta
AitorMenta Jan. 29 at 2:47 PM
$IMUX
1 · Reply
Tradergrows
Tradergrows Jan. 29 at 2:43 PM
$IMUX It’s an exciting time for the company, and also hopefully for shareholders -Vitt
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 29 at 4:21 AM
$IMUX RSI: 34.72, MACD: 0.0037 Vol: 0.05, MA20: 0.64, MA50: 0.65 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply